Growing company also announces expansion of leadership team and need to move to new, larger office space
MINNEAPOLIS (MARCH 23, 2015) — Verde Technologies, Inc., which develops research-based, scientifically proven solutions to reduce drug abuse, misuse and negative environmental impact, today announced new leadership for the growing company with Jason Sundby assuming the role of president and chief executive officer, effective immediately. Sundby will oversee the company’s fast-paced growth, including further expansion of the leadership team and cultivating partnerships for the Deterra® Drug Deactivation System, an innovative solution to preventing prescription drug abuse and misuse.
Sundby brings 30 years of experience in operations, risk management, administration and IT leadership to Verde Technologies. He has served on the Board of Directors since December 2012, and is a founding partner of Atlas Capital Partners. Prior to Atlas, Sundby was vice president of corporate administration at Regis Corporation and director of risk management for the Star Tribune. He completed his undergraduate studies at the University of Minnesota and continued his education at the Harvard School of Public Health and the Wharton School at the University of Pennsylvania.
“Verde Technologies is one of the most innovative players in the fight against the prescription drug abuse epidemic, and I look forward to leading the company through several exciting near-term initiatives and continued growth,” Sundby said. “Between our patented technology, strong leadership and rapidly growing customer base, we are well-poised to continue partnering with healthcare, community leaders and others committed to preventing prescription drug abuse in a simple, cost-effective manner.”
Verde also announced an expansion of its leadership team, including Christine Horton as chief commercial officer and the addition of Don Amorosi to its Board of Directors, as well as an upcoming move to a larger office space. The new location will provide the additional warehouse, lab and office space that Verde needs to continue its rapid expansion.
Horton brings more than 20 years of success and leadership in the medical device industry, including as the chief executive officer of CoreSpine Technologies, a spinal device company. Most recently, Horton was responsible for leading the successful market introduction of Cardiovascular Systems, Inc.’s first coronary product. She was also named a “Women to Watch in Business” by Minneapolis/St. Paul Business Journal and has been a regular guest lecturer for several years in the University of Minnesota’s Carlson School of Management program.
“Christine’s extensive experience and leadership in fundraising, marketing and sales made her the strongest choice for this position,” Sundby said. “Her diverse working knowledge of the regulatory and clinical fields makes her the perfect fit. We consider ourselves extremely lucky to have added her skills, experience and talent to our team.”
Amorosi has spent more than 21 years in the healthcare industry. He currently serves as senior vice president of managed markets at Upsher-Smith Laboratories. Prior to Upsher-Smith, Amorosi served as chief operating officer at Prime Therapeutics; vice president of trade relations at Omnicare; as well as leadership roles at Aetna, CIGNA and Rite Aid.
In February, Verde also announced a new Deterra partnership program available for companies and advocacy groups, such as manufacturers, pharmacy benefits managers, health insurers, pharmacies, hospitals and surgery centers, community organizations and police departments. The Deterra System utilizes patented MAT12® Molecular Adsorption Technology to deactivate unwanted, unneeded narcotics, antibiotics, transdermal patches and other prescription drugs, rendering them ineffective for misuse and safe for the environment.
About Verde Technologies, Inc.
Minneapolis-based Verde Technologies is a privately-owned company committed to developing research-based, scientifically proven solutions to reduce drug abuse and misuse. Originally introduced as Medsaway, the new Deterra Drug Deactivation System is powered by patented MAT12 Molecular Adsorption Technology, which deactivates prescription drugs using proprietary activated carbon. The technology is highly effective in adsorbing and firmly binding pharmaceuticals, rendering them inactive and ineffective for misuse and safe for the environment. For more information, please visit www.DeterraSystem.com.